Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

Phase 1/2 Completed 30 enrolled Dana-Farber Cancer Institute Brigham and Women's Hospital · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if rituximab is a safe and effective therapy for steroid-refractory chronic graft versus host disease (GVHD).

Timeline

Start: 2004-01
Primary completion: 2006-11
Completion: 2010-11

Publications

Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15;108(2):756-62. doi: 10.1182/blood-2006-01-0233. Epub 2006 Mar 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	—	Intravenous

Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

Summary

Timeline

Publications

Drugs

Indications